First‐line treatment of double‐hit and triple‐hit lymphomas: Survival and tolerance data from a retrospective multicenter French study-Reference-Cited by-同舟云学术

First‐line treatment of double‐hit and triple‐hit lymphomas: Survival and tolerance data from a retrospective multicenter French study

Published:2020-12-29 Issue:3 Volume:96 Page:302-311
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Laude Marie‐Charlotte¹^ORCID,Lebras Laure²,Sesques Pierre³^ORCID,Ghesquieres Herve³,Favre Simon⁴,Bouabdallah Krimo⁴,Croizier Carolyne⁵,Guieze Romain⁵,Drieu La Rochelle Laurianne⁶,Gyan Emmanuel⁶,Chin Roza⁷,Aurran‐Schleinitz Thérèse⁷,Marouf Amira⁸,Deau‐Fischer Bénédicte⁸,Coppo Paul⁹,Malot Sandrine⁹,Roussel Xavier¹⁰,Chauchet Adrien¹¹,Schwarz Marianne¹²,Bescond Charles¹³,Lamy de la Chapelle Thierry¹⁴,Bussot Lucile¹⁵,Carras Sylvain¹⁶,Burlet Bénédicte¹⁷,Rossi Cédric¹⁸,Daniel Adrien¹⁹,Morschhauser Franck²⁰,Subtil Fabien²¹,Michallet Anne‐Sophie²^ORCID

Affiliation:

1. Claude Bernard University Lyon France

2. Department of Hematology and Medical Oncology Centre Léon Bérard Lyon France

3. Department of Hematology Hospices Civils de Lyon Lyon France

4. Department of Hematology and Cell Therapy University Hospital of Bordeaux Bordeaux France

5. Department of Hematology and Cell Therapy Estaing University Hospital Clermont‐Ferrand France

6. Department of Hematology and Cell Therapy University Hospital of Tours Tours France

7. Department of Hemato‐Oncology Institut Paoli Calmette Marseille France

8. Department of Hematology Cochin Hospital Paris France

9. Department of Hematology and French Reference Center for Thrombotic Microangiopathies Saint‐Antoine Hospital Paris France

10. University of France‐Comté Besançon France

11. Department of Hematology University Hospital of Besançon Besançon France

12. University of Angers Angers France

13. Department of Hematology University Hospital of Angers Angers France

14. Department of Clinical Hematology University Hospital of Rennes Rennes France

15. University of Grenoble Grenoble France

16. Department of Hematology University Hospital of Grenobles Alpes Grenoble France

17. University of Dijon Dijon France

18. Department of Clinical Hematology University Hospital of Dijon Dijon France

19. University of Lille Lille France

20. Department of Hematology University Hospital of Lille Lille France

21. Department of Biostatistics Hospices Civils de Lyon Lyon France

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26068

Reference25 articles.

1. Le Guyader‐PeyrouS DefossezG DantonyE et al.Rapport ‐ Volume 2 Hémopathies malignes ‐ Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018 ‐ Juillet 2019 ‐ Ref: RAHMINCNAT19.https://www.e‐cancer.fr/Expertises‐et‐publications/Catalogue‐des‐publications/Rapport‐Volume‐2‐Hemopathies‐malignes‐Estimations‐nationales‐de‐l‐incidence‐et‐de‐la‐mortalite‐par‐cancer‐en‐France‐metropolitaine‐entre‐1990‐et‐2018. Accessed July 5 2019.

2. The 2016 revision of the World Health Organization classification of lymphoid neoplasms

3. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology

4. Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience

5. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma;Transplantation and Cellular Therapy;2024-09

2. Molecular Subtypes and the Role of TP53 in Diffuse Large B-Cell Lymphoma and Richter Syndrome;Cancers;2024-06-07

3. Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissues: B-cell Neoplasms;Modern Pathology;2024-04

4. Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level;Blood Research;2024-02-19

5. A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma;Blood Cancer Journal;2024-01-04